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ABSTRACT:  
The work is devoted to the study of the significance of the smoking factor in the realization of potentially positive 
cardiocytoprotective properties of metabolic correctors in the complex therapy of ischemic heart disease (IHD). A 
randomized study of 160 patients with stable angina pectoris was performed, 60 of them were smoking and 100 of 
them were non-smoking. The clinical efficiency of the treatment was assessed by the integral index of the treat-
ment effectiveness coefficient in percent (Cte,%). The individual effectiveness of metabolic correctors was eva-
luated in in vitro samples on blood leukocytes of patients using the DNA comet method. The subject of the study 
were trimetazidine, meldonium, phosphocreatine. A significant decrease in the clinical efficiency of treatment of 
smokers (Cte = 28.14 ± 4.10%) was found in comparison with non-smokers (Cte = 37.94 ± 2.42%, p = 0.03). 
Testing of metabolic correctors in vitro showed the appearance of genotoxic properties in trimetazidine, meldo-
nium and phosphocreatine when administered to smokers with IHD. It was found out prognostic inefficiency and 
inexpediency of metabolic drugs including in the complex pharmacotherapy of ischemic heart disease in smokers. 
The results of the study indicate the need for a personalized approach to the appointment of cardiac cytoprotectors 
to patients with IHD, depending on the presence of a smoking factor. 
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INTRODUCTION 
Ischemic heart disease (IHD) is one of the main 
causes of death in many countries of the world 
[1]. There is a different trend in the demographic 
indicators of mortality from cardiovascular dis-
eases in different European countries: in the 
West European region - a steady decline in mor-
tality, in the East European - the absence of such 
a decrease and even the growth of this indicator 
[2]. The Russian Federation, unfortunately, 
takes the leading position in Europe in terms of 
mortality from cardiovascular diseases [3]. 
Countries that have such a demographic situa-
tion are proposed to pay special attention to the 
correction of cardiovascular disasters risk fac-
tors, to study the causes  of  the low treatment 
effectiveness [1]. One of the causes of the insuf-
ficient effectiveness of the developed standards 
and recommendations for the treatment of IHD 
may be the lack of consideration of a complex of 
individual factors that influence on the outcome 
of pharmacotherapy. Scientific research in the 
field of personalization of the prescription of 
medicines for the treatment of socially signifi-
cant diseases is a priority in the Russian Federa-
tion [4]. The direction of personalized medicine 
is included in the modern concept of medicine 
development. President V.V. Putin declared the 
personalized medicine as one of the strategic 
directions of scientific and technological devel-
opment of Russia [5]. 
The smoking factor is a recognized risk factor 
for the development of cardiovascular disasters 
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[6,7,8,9]. According to some authors, the pres-
ence of a smoking factor determines the limita-
tion of the clinical efficiency of some antihyper-
tensive and antianginal agents [10,11]. To in-
crease the effectiveness of pharmacotherapy of  
IHD is recommended additionally to the drugs 
of basic therapy to prescribe drugs of the meta-
bolic series in order to provide cardiocytoprotec-
tion [7,8].  Trimetazidine, meldonium and phos-
phocreatine in experimental myocardial ische-
mia exhibit the properties of cardiac cytoprotec-
tors: they help stabilize cardiomyocyte mem-
branes, economize energy in the myocardium, 
and reduce the degree of hypoxia [12]. Whether 
the smoking factor is important for the realiza-
tion of potentially positive cardiocytoprotective 
properties of metabolic correctors in the com-
plex treatment of patients with ischemic heart 
disease is not described in literature. 
The purpose of this study was to determine the 
importance of the smoking factor in the individ-
ual effectiveness of metabolic correctors in the 
complex pharmacotherapy of ischemic heart 
disease. 
 
METHODS 
A randomized, open-label, controlled trial was 
conducted in 160 patients with ischemic heart 
disease: stable angina pectoris of I-III functional 
classes at the age of 37 to 81 years (mean age 
59.26 ± 0.74 years). In the majority of patients, 
angina pectoris was combined with hypertension 
(89.4%), rhythm disturbances (24.4%), post-
infarction cardiosclerosis (48.8%), chronic heart 
failure (94.4%), some with diabetes mellitus II 
type (23.1%). According to the presence of the 
smoking factor, the patients were divided into 
two groups: the 1st group consisted of 60 smok-
ing patients, the 2nd one  consisted of 100 non-
smoking patients. Patients underwent a compre-
hensive examination according to the recom-
mendations of the Russian Scientific Society of 
Cardiology [8]. The examination program in-
cluded a general blood test, a biochemical blood 
test, including a lipidogram, electrocardiography 
(ECG), echocardiography (EchoCG). 
Clinical efficiency of the treatment was assessed 
by standard criteria of angina pectoris functional 
class reducing, improving the clinical and he-
modynamic state of patients, improving the to-
lerance to physical load with the calculation of 
the integral coefficient of treatment efficiency in 
percent (Cte,%) according to our method (Patent 
of Ukraine No. 58859, 2003). The effectiveness 
of metabolic correctors was determined by test-
ing drugs in vitro on blood leukocytes of pa-
tients with the determination of their potential 
genotoxicity or genoprotective effect by the me-
thod of DNA comets according to the method 
developed by us [13]. The subject of our study 
were three drugs from the group of metabolic 
correctors: trimetazidine, meldonium and phos-
phocreatine. 
The prognostic significance of the smoking fac-
tor for the effectiveness of metabolic correctors 
was determined by the statistical method of 
Wald's prognostic analysis. Comparative analy-
sis between the groups was carried out by statis-
tical methods with the calculation of arithmetic 
means and their errors, median and quartiles, 
with an estimation of the reliability of differenc-
es in the Student's t-test and the Mann-Whitney 
U- test. Statistical processing of data was carried 
out using the software "Microsoft Excel 2007" 
and "SPSS for Windows 11.0". To evaluate the 
results of the study using the DNA comet me-
thod, the software "CometScoreТМ v.1.5" was 
used.   
 
RESULTS AND DISCUSSION  
To clarify the importance of the smoking factor 
in personalized pharmacotherapy of  ischemic 
heart disease, a comparative analysis of two 
groups of patients - smokers and non-smokers - 
was conducted. A number of significant differ-
ences were found out (Table 1 and Table 2). 
 
Table 1. : Comparative analysis of indicators of pathogenetic features and the effectiveness of IHD treatment in 
smokers and non-smokers 
Indicators Smoker patients, 
n=60 
Non-smoker patients, 
n=100 
Reliability of 
differences р 
Average age, years 55.77±1.15 61.27±0.87 0.001 
Height, m 1.73±0.01 1.67±0.01 0.001 
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Diabetes mellitus: duration in years 0.60±0.31 1.95±0.48 0.019 
Systolic blood pressure: mmHg 133.09±2.84 141.11±2.31 0.032 
Diastolic blood pressure: mmHg 96.67±4.01 83.07±2.41 0.007 
Hemoglobin, g / l 146.76±1.99 138.35±2.51 0.018 
Color indicator, units 0.93±0.01 0.89±0.01 0.012 
Glycated hemoglobin,% 5.58±0.15 6.19±0.29 0.065 
Potassium of blood, mmol / l 4.83±0.08 4.61±0.07 0.047 
Cholesterol total, mmol / l 5.01±0.17 5.70±0.16 0.007 
Lipoproteins of low density, mmol / l 3.05±0.16 3.56±0.15 0.030 
EchoCG: LV EDS, mm 55.51±1.27 51.94±0.96 0.025 
EchoCG: LV EDV, ml 151.20±6.77 122.43±4.45 0.001 
EchoCG: LV ESS, ml 72.94±5.82 55.91±3.89 0.012 
EchoCG: LV EF, % 53.41±1.85 57.78±1.36 0.054 
ECG: total voltage R in standard leads, mm 13.18±1.07 18.61±1.31 0.006 
Coefficient of treatment efficiency, % 28.14±4.10 37.94±2.42 0.030 
Note. The reliability of the differences was assessed according to Student's t-criterion. LV EDS- left 
ventricular end diastolic size, LV EDV - left ventricular end diastolic volume, LV ESS - left ventricular 
end sistolic size, LV ESV - left ventricular end sistolic volume; LV EF - left ventricular ejection frac-
tion. 
Table 2.Comparative analysis of indicators of pathogenetic featuresand the effectiveness of IHD treatment in 
smokers and non-smokers 
Indicators Smoker patients, n=60 Non-smoker patients, n=100 
Reliability of 
differences р 
Functional class of angina pectoris 2.63/ 
3.00 (2.00;3.00) 
3.00/ 
3.00 (2.00;3.25) 
0.028 
Diabetes mellitus: severity 
0.22/ 
0.00 (0.00;0.00) 
0.55/ 
0.00 (0.00;1.00) 
0.086 
Evaluation of the effectiveness of treat-
ment: subjective improvement, scores 
1.07/ 
1.00 (0.50;2.00) 
1.51/ 
1.00 (1.00;2.00) 
0.029 
Evaluation of the effectiveness of treat-
ment: objective improvement, scores 
0.99/ 
1.00 (0.50;2.00) 
1.29/ 
1.00 (1.00;2.00) 
0.075 
DNA initial status, DNA comet index 0.38/ 
0.10 (0.02;0.67) 
0.18/ 
0.06 (0.00;0.18) 
0.070 
DNA: phosphocreatine, the index of DNA 
comets 
0.83/ 
0.61 (0.07;1.37) 
0.30/ 
0.08 (0.00;0.38) 
0.004 
Note. The numerator is the arithmetic mean, the denominator is the median, 25% and 75% quartile. The 
reliability of the differences was evaluated according to the Mann-Whitney U-criterion. 
The average age of smokers was 55.77±1.15 years, that significantly lower, in comparison with non-
smokers 61.27±0.87 (p=0.001). Probably, due to the predominant influence of the age factor in this 
group of patients, the severity of the underlying disease (angina pectoris), the accompanying pathology 
(diabetes mellitus) and the lipid profile are more favorable. 
Smokers have a higher hemoglobin level and color index, which may indicate smoking as an additional 
factor of hypoxemia [14]. The objective status of smokers is significantly worse according to echocar-
diography and electrocardiography: the heart cavities are enlarged, the ejection fraction is lower, the 
violations of local contractility are more pronounced, the voltage on the ECG is reduced to the level of 
myocardial dystrophy (Table 1). 
According to our study, smokers in the initial status have significantly more damaged DNA compared 
to non-smokers (Table 2, Figure 1), which indicates on the presence of genotoxicity in components of 
tobacco smoke, that corresponds to the literature data [15]. 
The effectiveness of treatment of  smoking patients is significantly worse in terms of indicators of sub-
jective and objective improvement of the condition, the integral coefficient of treatment effectiveness. 
Thus, a significant difference was found between the groups in terms of the subjective improvement 
index, which in the 1st group was 1.07 / 1.00 (0.50, 2.00), in the 2nd 1.51 / 1.00 (1.00; 2.00) points (p 
<0.05); By the index of objective improvement of the condition - in the 1st group 0.99 / 1.00 (0.50, 
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2.00) points, in the 2nd 1.29 / 1.00 (1.00, 2.00) points (p = 0 , 07); by the index of the efficiency of 
treatment - in the 1st group of Cte was 28.14 ± 4.10%, in the 2nd group 37.94 ± 2.42% (p <0.05).
Other 
researchers also found a significant adverse effect of the smoking factor on the effectiveness of a num-
ber of drugs, including nitrates and antihypertensive agents [10,11]. Moreover, an extensive review of 
the literature on five electronic databases (Medline, PubMed Central, Cochrane library, Pascal and Web 
of Science), published by Pluvy I., Garrido I., Pauchot J. et al. (2015), showed the determining role of 
the smoking factor in violation of the healing process of the vascular wall after surgical treatment of 
coronary vessels, and the authors strongly recommend to patients quit smoking at least 4 weeks prior to 
surgery and 2 weeks after surgery. [14].  
Testing of metabolic correctors in vitro showed unambiguous genotoxicity of the latter in case of their 
introduction into the blood of smokers. Thus, the introduction of phosphocreatine into the in vitro test 
of blood leukocytes of smokers leads to even more destruction of the genome, in comparison with non-
smokers (Figure 1 and Table 2). Under the influence of trimetazidine in vitro, destruction of DNA was 
observed in patients who smoke 4.21 ± 1.61 cigarettes per day and DNA repair was observed in patients 
who smoke 0.41 ± 0.41 cigarettes per day (p <0.05). Under the influence of meldonium, destruction of 
DNA was observed in patients who smoke 3.94 ± 1.55 cigarettes per day and DNA repair was observed 
in patients who smoke 0.30 ± 0.30 cigarettes per day (p <0.05).
According to the Wald's prognostic 
analysis, the smoking factor determines the prognostic inefficiency and inexpediency of trimetazidine 
administration (the prognostic coefficient was minus 7, the coefficient of informative value of the sign 
was 0.49) and meldonium (the prognostic coefficient was minus 6, the coefficient of informative value 
of the sign was 0.38). 
 
Figure 1. The percentage of DNA in the tail of a comet of blood leukocytes of smokers and non-smokers with 
IHD in the initial state and when a phosphocreatine is introduced into the sample  (in vitro testing)  
Note. The reliability of the differences was assessed according to Student's t-criterion 
 
The search for possible causes of the detected 
prognostic ineffectiveness of metabolic correc-
tors in smoking patients with IHD showed a 
number of pathogenetic mechanisms for the 
formation of this phenomenon. Thus, smoking 
has a widespread and multifactorial effect on the 
human body [9,14]. Nicotine and tar in tobacco 
smoke contribute to the development of atheros-
clerosis by activating the processes of lipid pe-
roxidation and inflammation [4,16]. Reactive 
oxygen species and hydrogen peroxide are ca-
pable to destroy cell membranes and to fragment 
p<0,05 
p<0,05 
% DNA in the tail of a comet 
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DNA [17]. Endothelial dysfunction, hypoxia, 
immune disorders due to the influence of com-
ponents of tobacco smoke lead to damage to 
repair processes at the level of the vascular wall 
[14,18]. Restriction of the functional adaptive 
reserve of cells of the vascular wall to restore its 
resource determines the ineffectiveness of 
agents that stimulate metabolism [19]. 
Apparently, the genotoxicity of the components 
of tobacco smoke creates a certain direction of 
cellular metabolism in the direction of activation 
of catabolic processes, and with the introduction 
of drugs of the metabolic series, these unfavora-
ble processes of destruction of cell membranes 
and DNA are progressively developed. As bios-
timulants can not be administered in the pres-
ence of a cancer tumor, drugs that activate the 
metabolism should not be used for the treatment 
of ischemic heart disease in smoking patients, in 
order to avoid the stimulation of adverse effects 
of the components of tobacco smoke.
 
 
CONCLUSION 
The presence of the smoking factor in patients 
with ischemic heart disease (stable angina pecto-
ris) determines a significant decrease in the clin-
ical effectiveness of complex treatment and 
causes prognostic inefficiency and inexpediency 
of using metabolic correctors as cardiac cytopro-
tectors due to the formation of their individual 
genotoxicity in this category of patients. The 
results of the study indicate the need for a per-
sonalized approach to the appointment of car-
diac cytoprotectors to patients with IHD, de-
pending on the presence of a smoking factor.
 
 
SUMMARY 
1. A significant decrease in the clinical effi-
ciency of ischemic heart disease treatment 
was found in smokers (Cte = 28.14 ± 4.10%) 
in comparison with non-smokers (Cte = 
37.94 ± 2.42%, p = 0.03). 
2. Testing of metabolic correctors in vitro 
showed the appearance of genotoxic proper-
ties in trimetazidine, meldonium and phos-
phocreatine when administered to smokers 
with IHD. 
3. It was found out prognostic inefficiency and 
inexpediency of metabolic drugs including in 
the complex pharmacotherapy of ischemic 
heart disease in smokers. 
4. The results of the study indicate the need for 
a personalized approach to the appointment 
of cardiac cytoprotectors to patients with 
IHD, depending on the presence of a smok-
ing factor. 
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